The Respond Trial—Rivastigmine to Stabilise Gait in Parkinson’s Disease a Phase II, Randomised, Double Blind, Placebo Controlled Trial to Evaluate the Effect of Rivastigmine on Gait in Patients with Parkinson’s Disease Who Have Fallen
The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.